Cover Image
市场调查报告书

新兴市场上生物相似药趋势

Biosimilars in Emerging Markets

出版商 Datamonitor Healthcare 商品编码 573567
出版日期 内容信息 英文 116 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
新兴市场上生物相似药趋势 Biosimilars in Emerging Markets
出版日期: 2017年04月20日 内容信息: 英文 116 Pages
简介

本报告提供新兴市场上生物相似药市场相关调查,汇整市场概要和新兴市场趋势,各国趋势等数据。

摘要整理

生物相似药市场

  • 生物制品正在改变药物疗法,但对医疗保健财政形成压力
  • 已开发国家市场的不确定性和混乱推迟了生物仿制药的批准和推广
  • 后续的生物制剂在新兴市场取得了进展
  • 市场动态使得亚洲企业在该领域取得重大的领先优势
  • 生物仿制促进要素超过了新兴市场的限制
  • 参考

新兴市场生物相似药

  • 多样性反映了独特的该国市场趋势
  • 早期的鼻祖目标受到严重的打击
  • 目前,胰岛素,etanercept和一群Mabs正辈受注目
  • 最近的发布引发了金砖四国生物仿制药市场价值的大幅上涨
  • 本地企业已经抓住了早期的领导地位
  • 一些新兴市场的价格下滑幅度可能不及预期
  • BRIC-MS生物仿制药管道库存丰富
  • 单抗主导了最流行的生物仿制药目标
  • 当地的主要企业正在全球生物仿制药阶段发挥重要作用
  • 其他金砖四国的参与者将在“三大”之后进入高度监管的市场
  • 然而,许多本地企业的长期前景将不太乐观
  • 参考

巴西

  • 国内的专家不足限制早期活动
  • 海外参与企业进入相关领域 其他

俄罗斯

  • 后续产品已经改变了主要细分市场
  • 后续生物制剂的监管途径终于起草
  • Roche诉讼失败给原始生物专利带来了坏消息
  • 新规定为后续生物制品确定最高限价 其他

印度

  • 类似的生技药品认证流程仍在稳定持续
  • 由于新的指导方针可更早获得后续的生物制剂

中国

  • "早期生物标的"
  • 法律规章的手续
  • 新法规要求事项

墨西哥

  • 早期的后续产品取得重大进展
  • 提高后续生物制剂的监管标准

韩国

  • 政府的支持推动了对生物仿制药的早期投资
  • 积极的方法在全球及国内均带来成果

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: DMKC0172273

Follow-on biologics have been embraced enthusiastically in most emerging markets, where they promise to deliver much-needed improvements in access to a generation of products that remains beyond the reach of many patients. They have been registered in substantial numbers, and have been prescribed and purchased widely, expanding treatment populations and eroding originator revenues. By the early part of this decade, follow-on biologics were generating annual sales of around $600m in China alone. With follow-on products winning key government tenders in countries like Mexico and Russia, and being purchased by a growing number of patients in self-pay markets such as India, aggregate sales of copy biologics in the six BRIC-MS (Brazil, Russia, India, China, Mexico, and South Korea) countries now almost certainly exceed $1.5bn.

Many follow-on biologics being sold in BRIC-MS countries were subject to cursory regulatory reviews, and would not meet biosimilarity standards required to obtain marketing authorization in highly regulated markets. Some have been tested more rigorously, however, and manufacturers based in South Korea and India have begun to emerge as major players on the global biosimilars stage. In the meantime, regulators in all six BRIC-MS countries have introduced new, more rigorous requirements for the approval of follow-on biologics. These will trigger a degree of restructuring in most emerging biosimilar markets, piquing the interest of international players. BRIC-MS policymakers are keen to encourage the development of local manufacturing capabilities in the biologics sector, however, and foreign companies attempting to service emerging markets via biosimilar imports will face challenging administrative, regulatory, and pricing barriers.

Throughout this report, the term "follow-on biologic" is used generically, referring to any non-originator biologic, whether "biosimilar" or not. Despite its title, the report includes information on products that could not be described accurately as "biosimilars," a term reserved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for biological medicines that are "similar to another biological medicine already authorized for use." To obtain an EMA or FDA marketing authorization, a biosimilar application must contain data showing that the product is "similar to the reference medicine" and that there are "no meaningful differences" between the two products in terms of quality, safety, or efficacy.

Early follow-on biologics commercialized in most BRIC-MS countries were subject to much less onerous requirements, and many would fail the EMA's or FDA's biosimilarity test. These are often described as "copy biologics." Regulators in all six BRIC-MS markets have since implemented much tighter requirements governing the approval of follow-on products, however. While these refer variously to "biological products" (Brazil), "similar biologics" (India), or "biocomparables" (Mexico), all now require the production of substantive clinical data. In most cases this includes comparability data and, as such, it is reasonable to describe products approved under these new regulatory frameworks as biosimilars.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • Low IP and regulatory barriers provided an early path to market
  • Original biologics have been hit hard in BRIC-MS markets
  • Tighter regulations have begun to affect BRIC-MS market dynamics
  • Governments remain firmly on the side of local manufacturers
  • Leading BRIC-MS players are spreading their wings
  • The long-term potential of BRIC-MS biosimilar markets is huge

THE BIOSIMILARS MARKET

  • Biologics are transforming drug therapy, but are heaping pressure on healthcare finances
  • Uncertainty and confusion delayed biosimilar approval and uptake in developed markets
  • Follow-on biologics forged ahead in emerging markets
  • Market dynamics handed Asian players a significant lead in the sector
  • Biosimilar drivers outweigh constraints in emerging markets
  • Bibliography

THE BIOSIMILARS LANDSCAPE IN EMERGING MARKETS

  • Diversity reflects unique national market dynamics
  • Early originator targets suffer badly
  • Insulins, etanercept, and a raft of Mabs are now in the firing line
  • Recent launches have triggered a sharp increase in BRIC-MS biosimilar market values
  • Local players have grabbed early leadership positions
  • Price erosion in some emerging markets may be less dramatic than anticipated
  • BRIC-MS biosimilar pipelines are richly stocked
  • Mabs dominate the list of most popular biosimilar targets
  • Local champions are now pursuing roles on the global biosimilars stage
  • Other BRIC-MS players will follow the "big three" into highly regulated markets
  • However, long-term prospects for many local players will be less rosy
  • Bibliography

BRAZIL

  • Lack of local expertise limits early activity
  • Foreign players step into the relative void
  • ANVISA moves early on regulatory guidance for follow-on biologics
  • Government pursues biologics import substitution drive
  • SUS procurement rules and PDPs complicate the biosimilar pricing environment
  • Foreign companies eye biosimilar Mab opportunities
  • Bibliography

RUSSIA

  • Follow-on products have transformed key market segments
  • A regulatory pathway for follow-on biologics is finally drawn up
  • Roche litigation failure spells bad news for original biologic patents
  • New rules establish ceiling prices for follow-on biologics
  • Import substitution and drug coverage aspirations to drive the market
  • Biosimilar trial activity has rocketed
  • Bibliography

INDIA

  • Steady flow of "similar biologic" approvals continues
  • New guidelines promise earlier access for follow-on biologics
  • Legal battles persist, even where patents are not an issue
  • Follow-on products drive prices down, but affordability remains a key issue
  • Market prospects remain positive
  • Bibliography

CHINA

  • Locals home in early on "easy" biologic targets
  • Regulators step up requirements for follow-on biologics
  • New regulatory requirements will trigger a local industry shake-out
  • Bibliography

MEXICO

  • Early follow-on products make significant inroads
  • Raising the regulatory bar for follow-on biologics
  • Probiomed loses patent spat with Roche over rituximab
  • Mabs feature prominently in the biocomparables pipeline
  • Changes in the competitive landscape are anticipated
  • Bibliography

SOUTH KOREA

  • Government support drives early investment in biosimilars
  • Pro-active approach bears global as well as local fruit
  • Domestic launches force Korean biologic prices down
  • With global markets in their sights, regulators set the biosimilars bar high
  • Remsima spearheads a biologics export boom
  • Launch activity is beginning to heat up
  • Bibliography

APPENDIX

  • About the author
  • Scope
  • Definitions
  • Methodology

LIST OF FIGURES

  • Figure 1: Contribution of cancer and diabetes to overall mortality in emerging markets
  • Figure 2: The second wave of follow-on biologics in BRIC-MS markets
  • Figure 3: Leading companies in India by volume of approved/launched follow-on biologics
  • Figure 4: Status of biosimilar clinical trials in the BRIC-MS markets
  • Figure 5: Biosimilar development by country and phase
  • Figure 6: Most popular biosimilar development targets in the BRIC-MS countries
  • Figure 7: Brazil: biosimilar competition in the pipeline, by volume per reference biologic
  • Figure 8: Russia: biosimilar companies by volume of approved or launched biosimilars
  • Figure 9: Russia: biosimilar competition in the pipeline, by volume per reference biologic
  • Figure 10: Russia: biosimilar companies by volume of biosimilars in preclinical through to Phase III development
  • Figure 11: Original biologics facing competition from more than one follow-on product in India
  • Figure 12: Companies with more than two approved/launched follow-on biologics in India
  • Figure 13: India: biosimilar competition in the pipeline, by volume per reference biologic
  • Figure 14: India: biosimilar companies by volume of biosimilars in preclinical through to Phase III development
  • Figure 15: Biosimilar Mabs in the Mexican development pipeline
  • Figure 16: Foreign company involvement in preclinical through to Phase III biosimilar development in South Korea
  • Figure 17: Five most popular targets of biosimilar development activity in South Korea

LIST OF TABLES

  • Table 1: Global sales of best-selling pharmaceutical brands, 2015
  • Table 2: Biosimilars and generics: key differences
  • Table 3: Major tie-ups between leading BRIC-MS biosimilar players and global/regional partners
  • Table 4: Regulating follow-on biologics/biosimilars in the BRIC-MS markets
  • Table 5: Biosimilar development activity in the BRIC-MS markets
  • Table 6: US, EU, and Japanese approvals of Biocon, Celltrion, and Samsung Bioepis biosimilars
  • Table 7: US, EU, and Japanese biosimilar filings by Biocon, Celltrion, and Samsung Bioepis
  • Table 8: Biocon's biosimilars pipeline
  • Table 9: Celltrion's biosimilars pipeline*
  • Table 10: Samsung Bioepis's late-stage biosimilars pipeline
  • Table 11: Availability of four key follow-on biologics in Brazil
  • Table 12: Average time taken to authorize biological drugs in Brazil
  • Table 13: PDP contracts awarded for key biologics, 2015/2016
  • Table 14: Brazil: biosimilar companies by volume of biosimilars in preclinical through to Phase III development
  • Table 15: Follow-on Mab products approved in Russia
  • Table 16: First approval dates for Mab-based follow-on biologics in India
  • Table 17: Biologic price erosion following the arrival of follow-on products in India
  • Table 18: Impact of biosimilar competition in China's tumor necrosis factor inhibitor market
  • Table 19: Shanghai Henlius Biotech's biosimilar monoclonal antibody pipeline
  • Table 20: Follow-on filgrastims registered and commercialized in Mexico
  • Table 21: Key biosimilar approvals in South Korea, 2012-16
Back to Top